Posted by Michael Wonder on 22 Sep 2021
NICE terminates yet another appraisal of a medicine for multiple myeloma
22 September 2021 - This is the eleventh terminated appraisal of a medicine for multiple myeloma. London, we have a problem.
NICE is unable to make a recommendation on the use of isatuximab (Sarclisa) in combination with carfilzomib (Kyprolis) and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma because Sanofi did not provide an evidence submission.
